Related Experiment Video

Updated: Sep 4, 2026

A Rat Model of Mild Intrauterine Hypoperfusion with Microcoil Stenosis
06:19

A Rat Model of Mild Intrauterine Hypoperfusion with Microcoil Stenosis

Published on: January 7, 2018

Neonatal outcome gains from sFlt-1/PlGF testing in hypertensive disorders of pregnancy: Modeled estimates from

Teofilo Borunda Duque1, Padmashree C Woodham2, Amalia Brawley2

  • 1Thermo Fisher Scientific, Waltham, MA, USA.

Pregnancy Hypertension
|September 2, 2026
PubMed

Hypertensive disorders of pregnancy (HDP) affect the incidence of preterm birth. The sFlt-1/PlGF ratio test predicts preeclampsia progression, but its effect on neonatal outcomes is understudied. This study estimated reductions in neonatal mortality and morbidity through sFlt-1/PlGF-guided management for hospitalized patients with HDP. Using a decision-analytic model with PRAECIS and BEACON data and neonatal outcomes from a U.S. cohort of 760,000 infants, outcomes were estimated for patients with HDP at 24-35 weeks' gestation. Results indicated biomarker-guided management was associated with averting 1 death and 75 morbidity cases per 1000 preterm deliveries. sFlt-1/PlGF-guided management could reduce preterm neonatal mortality and morbidity.

Keywords:
Biomarker-guided managementHypertensive disorders of pregnancyNeonatal outcomesPreeclampsiaPretermsFlt-1/PlGF

More Related Videos

Comprehensive Evaluation of the Effectiveness and Safety of Placenta-Targeted Drug Delivery Using Three Complementary Methods09:04

Comprehensive Evaluation of the Effectiveness and Safety of Placenta-Targeted Drug Delivery Using Three Complementary Methods

Published on: September 10, 2018

Model Surgical Training: Skills Acquisition in Fetoscopic Laser Photocoagulation of Monochorionic Diamniotic Twin Placenta Using Realistic Simulators09:51

Model Surgical Training: Skills Acquisition in Fetoscopic Laser Photocoagulation of Monochorionic Diamniotic Twin Placenta Using Realistic Simulators

Published on: March 21, 2018

Related Concept Videos

Teratogenicity01:07

Teratogenicity

The ability of a drug to produce structural deformations and functional abnormalities in the developing embryo or the fetus is called teratogenicity, and the drug producing this effect is known as a teratogen. Teratogenic effects include stillbirth, miscarriage, intrauterine growth restriction, and neurocognitive delay. A teratogen may affect the embryo at different stages of development, which is important in determining the type and extent of the damage. During blastocyst formation, the early...